Gastric Cancer trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Gastric Cancer. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month10 studies across 7 companies, in the next 180 days.
August 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| NRIX | Nurix Therapeutics, Inc. | A Study of NX-1607 in Adults With Advanced MalignanciesNCT05107674Incidence of treatment-emergent adverse events (TEAEs), including Grade ≥ 3 TEAEs, treatment-emergent serious adverse events (SAEs), TEAEs leading to study drug discontinuation, and deaths due to TEAEs | Phase 1 | Recruiting | 2026-08-31 | in 11 d | 2025-09-09 |
September 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2NCT07143604Objective Response Rate (ORR) | Phase 2 | Active, not recruiting | 2026-09-28 | in 39 d | 2026-06-17 |
October 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| BMY | Bristol-Myers Squibb | Evaluation of Esophagogastric Cancer Treatment With Nivolumab in Daily Clinical PracticeNCT07663786observationalOverall survival (OS) among participants treated with first-line nivolumab | — | Active, not recruiting | 2026-10-01 | in 42 d | 2026-06-23 |
November 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2NCT06219941Incidence of adverse events (AEs), serious AEs (SAEs). Changes from baseline in clinical laboratory parameters, vital signs, ECGs and physical examination. Rate of AEs leading to discontinuation of AZD0901, Occurrence of DLTs. | Phase 2 | Recruiting | 2026-11-17 | in 89 d | 2026-07-29 |
December 2026 5
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid TumoursNCT06147037Evaluate safety and tolerability of [111In]-FPI-2107, FPI-2053, and [225Ac]-FPI-2068 | Phase 1 | Active, not recruiting | 2026-12-31 | in 133 d | 2026-07-07 |
| BMY | Bristol-Myers Squibb | A Study of Nivolumab Plus Chemotherapy in First Line Treatment of Adult Participants With Advanced or Metastatic Gastric CancerNCT05165264observationalOverall Survival (OS) | — | Active, not recruiting | 2026-12-31 | in 133 d | 2025-03-03 |
| JAZZ | Jazz Pharmaceuticals | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsNCT06695845Confirmed Objective Response Rate (cORR) per RECIST Version 1.1, as assessed by ICR | Phase 2 | Recruiting | 2026-12-31 | in 133 d | 2026-07-10 |
| MNPR | Monopar Therapeutics | Dose-Escalation of MNPR-101-PCTA-177Lu in Solid TumorsNCT06617169Identify the dose-limiting toxicities (DLTs) of fractionated MNPR-101-PCTA-177Lu dosing and their frequency | Phase 1 | Recruiting | Dec 2026 | ≤ 133 d | 2025-05-21 |
| PFE | Pfizer | Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)NCT05382364Percentage of participants with ≥1 adverse event (AE) | Phase 1 | Active, not recruiting | 2026-12-31 | in 133 d | 2026-03-12 |
January 2027 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| ELVN | Enliven Therapeutics | ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast CancerNCT06328738Incidence of dose limiting toxicities (DLTs; Phase 1a only) | Phase 1 | Active, not recruiting | Jan 2027 | ≤ 164 d | 2025-11-19 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Gastric Cancer
most recently updated first179 studies match. Showing the first 100 of 179 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | — | Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid MalignanciesNCT04644068The number of subjects with adverse events/serious adverse events | Phase 1/2 | Active, not recruiting | Drug: AZD5305, Paclitaxel, Carboplatin, T- Dxd, Dato-DXd, Camizestrant | Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer, Additional Indications Below for Module 4 and 5, Non-small Cell Lung Cancer, Colorectal Cancer, Bladder Cancer, Gastric Cancer, Biliary Cancer, Cervical Cancer, Endometrial Cancer, Small Cell Lung Cancer Only in Module 5 | 702 | 2020-11-12 | 2027-05-28 | in 281 d | 2026-08-19 |
| 4568.T | Daiichi Sankyo | $31.7B | Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in ChinaNCT06846996observationalReal-world Time to Treatment Failure (rwTTF) | — | Recruiting | Drug: Trastuzumab deruxtecan (T-DXd) | HER2-positive Gastric Cancer, HER2-positive Gastroesophageal Junction | 260 | 2025-02-27 | 2027-07-31 | in 345 d | 2026-08-18 |
| PFE | Pfizer | $155.3B | Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal CancerNCT07392892Phase 2: Confirmed Objective response rate (ORR) using RECIST 1.1 as assessed by investigator | Phase 2/3 | Recruiting | Biological: PF-08634404, Nivolumab · Drug: Chemotherapy | Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma | 840 | 2026-05-14 | 2031-07-22 | in 1,797 d | 2026-08-17 |
| PFE | Pfizer | $155.3B | Tucatinib Continuation StudyNCT07768358To monitor the safety and tolerability of tucatinib | Phase 4 | Not yet recruiting | Drug: tucatinib | HER2-positive Breast Cancer, Cervical Cancer, Biliary Tract Neoplasms, Urothelial Cancer, Advanced Non-Small Cell Lung Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma (GEC), Colorectal Cancer | 175 | 2026-08-24 | 2032-03-13 | in 2,032 d | 2026-08-17 |
| AZN | AstraZeneca | — | Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)NCT05489211Objective response rate (ORR) | Phase 2 | Recruiting | Drug: Datopotamab deruxtecan (Dato-DXd), Capecitabine, 5-Fluorouracil, Volrustomig, Carboplatin, Bevacizumab, Rilvegostomig, Prednisone/ prednisolone, Cisplatin | Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Urothelial Cancer, Biliary Tract Cancer | 454 | 2022-09-06 | 2027-10-01 | in 407 d | 2026-08-13 |
| NXTC | NextCure, Inc. | $30M | A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid TumorsNCT05572684results2026-08-13Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0 | Phase 1/2 | Terminatedsponsor's stated reason: Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial. | Drug: NC410, pembrolizumab | Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High, Microsatellite Stable, Ovarian Cancer, Gastric Cancer, Colo-rectal Cancer, Esophageal Cancer, Endometrial Cancer, Head Neck Cancer, Cervical Cancer, Lung Cancer | 97 | 2022-10-06 | 2025-04-30actual | — | 2026-08-13 |
| AVBP | ArriVent BioPharma, Inc. | $1.5B | A Study of MRG007 (ARR-217) in Patients With Advanced Solid TumorsNCT07066657Dose Limiting Toxicity (DLT) - Phase Ia | Phase 1 | Recruiting | Drug: MRG007, MRG007 and Bevacizumab | Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer | 572 | 2025-07-25 | Mar 2028 | ≤ 589 d | 2026-08-13 |
| MGNX | MacroGenics | $261M | A Study of MGC026 in Participants With Advanced Solid TumorsNCT06242470Number of participants with adverse events (AEs) and serious AEs (SAEs), AEs leading to dose delay, AEs leading to dose reduction, AEs leading to treatment discontinuations, AEs meeting criteria for dose limiting toxicity, and AEs of special interest. | Phase 1 | Recruiting | Biological: MGC026 Dose Escalation, MGC026 Dose for Expansion | Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Sarcoma, Endometrial Cancer, Melanoma, Castration Resistant Prostatic Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Gastro-esophageal Cancer, Pancreas Cancer, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Platinum-resistant Ovarian Cancer, Breast Cancer, Ovarian Cancer, Esophageal Squamous Cell Cancer (SCC) | 250 | 2024-03-06 | May 2028 | ≤ 650 d | 2026-08-11 |
| 4568.T | Daiichi Sankyo | $31.7B | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid TumorsNCT06172478Number of Participants With Objective Response Rate Assessed by Investigator Following HER3-DXd Monotherapy (All Cohorts Except Prostate Cancer Cohort) | Phase 2 | Recruiting | Drug: HER3-DXd | Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer, Non-small Cell Lung Cancer (NSCLC), Lung Cancer, Breast Cancer | 740 | 2024-02-26 | 2027-09-01 | in 377 d | 2026-08-10 |
| 4568.T | Daiichi Sankyo | $31.7B | Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerNCT06731478Progression Free Survival (PFS) | Phase 3 | Recruiting | Drug: Trastuzumab Deruxtecan, pembrolizumab, Trastuzumab, Chemotherapy | Gastric Cancer, Gastroesophageal Junction Cancer | 726 | 2025-02-27 | 2028-06-01 | in 651 d | 2026-08-10 |
| ONC | BeOne Medicines | $545.6B | A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaNCT07043400Model-Predicted Steady State Trough Concentration (Ctrough) of Tislelizumab | Phase 3 | Recruiting | Drug: Subcutaneous Tislelizumab, Intravenous Tislelizumab, Cisplatin, Leucovorin, 5-fluorouracil (5-FU), Oxaliplatin, Capecitabine | Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 351 | 2025-08-27 | 2027-10-30 | in 436 d | 2026-08-07 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4257496 in Participants With Cancer (OMNIRAY)NCT07114601Phase 1a Dose Escalation: Maximum Tolerated Dose of LY4257496 | Phase 1 | Recruiting | Drug: LY4257496, Standard of Care Anticancer Therapies · Diagnostic test: LY4257529 | Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Esophageal Neoplasms | 421 | 2025-08-06 | Apr 2030 | ≤ 1,349 d | 2026-08-06 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4337713 in Participants With FAP-Positive Solid TumorsNCT07213791Phase 1a: Percentage of Participants with Dose Limited Toxicity (DLT) Toxicities | Phase 1 | Recruiting | Drug: LY4337713 | Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Cholangiocarcinoma | 241 | 2025-10-22 | Jul 2028 | ≤ 711 d | 2026-08-06 |
| STRO | Sutro Biopharma, Inc. | $365M | A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic CancerNCT07227168Part 1A: Number of participants with Dose-limiting Toxicities (DLTs) | Phase 1 | Recruiting | Drug: STRO-004, Pembrolizumab | Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer, Gastric Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Cervical Cancer, Endometrial Cancer, Urothelial Cancer | 200 | 2025-11-07 | Dec 2027 | ≤ 498 d | 2026-08-06 |
| IDYA | IDEAYA Biosciences | $3.7B | A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid TumorsNCT07277413Incidence of Dose-limiting Toxicities (DLTs) of IDE892 (Parts 1 and 3) | Phase 1 | Recruiting | Drug: IDE892, IDE397 | NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus, Squamous Cell Car. - Esophagus, Urothelial Carcinoma (UC), Bladder Cancer, Mesothelioma, Pleural Mesothelioma, Peritoneal Mesothelioma, Non-Small Cell Lung Cancer NSCLC, Pancreatic Cancer, Biliary Tract Carcinoma | 260 | 2026-03-04 | 2028-04-30 | in 619 d | 2026-08-05 |
| AZN | AstraZeneca | — | Study for AZD4360 in Participants With Advanced Solid TumoursNCT06921928Incidence of participants with Dose-Limiting Toxicity (in dose escalation cohort), Adverse events (AEs) , Serious Adverse Events (SAEs) and AEs leading to discontinuation of AZD4360 | Phase 1/2 | Active, not recruiting | Drug: AZD4360 | Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma | 31 | 2025-04-29 | 2027-03-31 | in 223 d | 2026-07-31 |
| RCUS | Arcus Biosciences, Inc. | $3.8B | Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced CancersNCT05891171Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 1 | Active, not recruiting | Drug: AB598, Zimberelimab, Fluorouracil, Leucovorin, Oxaliplatin | Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer (GEJ), Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Renal Cell Carcinoma (RCC), Triple Negative Breast Cancer (TNBC) | 40 | 2023-10-13 | Sep 2027 | ≤ 406 d | 2026-07-30 |
| INBX | Inhibrx Biosciences, Inc | $1.4B | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)NCT04198766Frequency of adverse events of INBRX-106 as single agent and in combination with pembrolizumab | Phase 1/2 | Recruiting | Drug: INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg, Carboplatin AUC-5, Carboplatin AUC-6, Pemetrexed 500 mg/m2, Cisplatin 75mg/m2, Paclitaxel 200mg/m2, Nab paclitaxel 100mg/m2, Gemcitabine (1000 mg/m2) | Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma, Resectable Non-Small-Cell Lung Cancer | 340 | 2019-12-10 | Jul 2033 | ≤ 2,537 d | 2026-07-29 |
| AMGN | Amgen | $229.9B | A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.NCT05322577Part 1: Number of Participants Who Experience a Dose-limiting Toxicity (DLT) | Phase 1/2 | Terminatedsponsor's stated reason: Sponsor Decision | Drug: Bemarituzumab, CAPOX, SOX, Nivolumab | Gastric Cancer, Gastroesophageal Junction Cancer | 72 | 2022-05-17 | 2025-11-21actual | — | 2026-07-29 |
| AZN | AstraZeneca | — | AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2NCT06219941Incidence of adverse events (AEs), serious AEs (SAEs). Changes from baseline in clinical laboratory parameters, vital signs, ECGs and physical examination. Rate of AEs leading to discontinuation of AZD0901, Occurrence of DLTs. | Phase 2 | Recruiting | Drug: AZD0901, 5-Fluorouracil, Leucovorin, l-leucovorin, Irinotecan, Nanoliposomal Irinotecan, Gemcitabine | Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma | 226 | 2023-12-13 | 2026-11-17 | in 89 d | 2026-07-29 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsNCT05208762Number of participants with adverse events (AEs) | Phase 1 | Recruiting | Drug: PF-08046054, pembrolizumab | Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Neoplasms, Gastric Cancer, Endometrial Cancer, Pancreatic Adenocarcinoma, Hepatocellular Carcinoma | 714 | 2022-10-25 | 2028-01-05 | in 503 d | 2026-07-22 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of SGN-CEACAM5C in Adults With Advanced Solid TumorsNCT06131840Number of participants with adverse events (AEs) | Phase 1 | Recruiting | Drug: PF-08046050, bevacizumab, 5-Fluorouracil (5-FU), Oxaliplatin, Leucovorin (LV) | Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small Cell Lung Carcinoma | 914 | 2023-11-20 | 2029-09-12 | in 1,119 d | 2026-07-22 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid TumorsNCT06157892Number of participants with dose limiting toxicities (DLTs) in dose escalation phase | Phase 2 | Active, not recruiting | Drug: disitamab vedotin, tucatinib | Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms, Metastatic Breast Cancer, Metastatic Gastric Cancer, Advanced Breast Cancer, Advanced Gastric Cancer | 54 | 2024-05-20 | 2029-07-28 | in 1,073 d | 2026-07-22 |
| SNY | Sanofi | — | A Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction CancerNCT07692204Objective response rate | Phase 2 | Recruiting | Drug: SAR445877 | Gastric Cancer, Oesophageal Carcinoma | 30 | 2026-07-01 | 2028-08-02 | in 713 d | 2026-07-20 |
| AMGN | Amgen | $229.9B | Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.NCT05111626Part 1: Number of Participants Who Experienced DLTs | Phase 3 | Terminatedsponsor's stated reason: Study was terminated by sponsor | Drug: Bemarituzumab, Nivolumab, Chemotherapy · Other: Placebo | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 515 | 2022-03-14 | 2025-10-14actual | — | 2026-07-17 |
| NTHI | Neonc Technologies, Inc. | $143M | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisNCT06047379Phase 1: safety and tolerability of increasing dose levels of orally administered NEO212 alone in patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or patients with select solid tumors with uncontrolled metastases to the brain | Phase 1/2 | Recruiting | Drug: NEO212 Oral Capsule, Ipilimumab, Pembrolizumab, Nivolumab, Regorafenib, Carboplatin, Paclitaxel, FOLFIRI Protocol, Bevacizumab | Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Microsatellite Instability-High Solid Malignant Tumor, Mismatch Repair Deficient Solid Malignant Tumor, Microsatellite Instability-High Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Squamous Cell Carcinoma, Urothelial Carcinoma | 134 | 2023-11-01 | 2027-02-28 | in 192 d | 2026-07-16 |
| AZN | AstraZeneca | — | A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.NCT02734004results2023-10-13Initial Stage Cohorts: Disease Control Rate (DCR) at Week 12 | Phase 1/2 | Active, not recruiting | Drug: Olaparib, MEDI4736, Bevacizumab | Ovarian, Breast, SCLC, Gastric Cancers | 264 | 2016-03-17 | 2021-09-17actual | — | 2026-07-14 |
| AZN | AstraZeneca | — | Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)NCT04379596Part 1: Occurrence of adverse events (AEs) and serious adverse events (SAEs), graded according to NCI CTCAE v5.0 | Phase 2 | Recruiting | Drug: Fluorouracil (5-FU), Capecitabine, Oxaliplatin, Trastuzumab deruxtecan, Cisplatin · Biological: Durvalumab, Trastuzumab, Pembrolizumab, Volrustomig, Rilvegostomig | Gastric Cancer | 450 | 2020-06-03 | 2027-06-01 | in 285 d | 2026-07-10 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsNCT06695845Confirmed Objective Response Rate (cORR) per RECIST Version 1.1, as assessed by ICR | Phase 2 | Recruiting | Drug: Zanidatamab | Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer, Colorectal Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Urothelial Carcinoma, Salivary Gland Cancer, Pancreatic Cancer, HER-2 Protein Overexpression | 200 | 2025-01-14 | 2026-12-31 | in 133 d | 2026-07-10 |
| GILD | Gilead Sciences | $177.9B | Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal AdenocarcinomasNCT07546812Objective Response Rate (ORR) | Phase 2 | Recruiting | Drug: Denikitug, Nivolumab, Ramucirumab, Paclitaxel | HER2-negative, Gastroesophageal Junction, Esophageal Adenocarcinoma, Gastric Adenocarcinoma | 120 | Jul 2026 | Jan 2030 | ≤ 1,260 d | 2026-07-10 |
| AZN | AstraZeneca | — | AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2NCT06346392Progression Free Survival (PFS) in all randomized participants | Phase 3 | Active, not recruiting | Drug: AZD0901, AZD0901, Ramucirumab+ paclitaxel, Paclitaxel, Docetaxel, Irinotecan, TAS-102, Apatinib | Gastric Cancer, Gastroesophageal Junction Cancer | 594 | 2024-03-04 | 2026-05-31actual | — | 2026-07-09 |
| IMNM | Immunome, Inc. | $3.1B | A Phase 1 Study of IM-1617 in Participants With Advanced CancerNCT07578571Evaluate the safety and tolerability of IM-1617 in participants with unresectable locally advanced or metastatic solid tumors by incidence of adverse events (AEs) and serious adverse events (SAEs) | Phase 1 | Recruiting | Drug: IM-1617 | Colorectal Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Esophageal Cancer, Stomach Cancer, Cancer | 175 | 2026-05-21 | Jan 2029 | ≤ 895 d | 2026-07-09 |
| ONC | BeOne Medicines | $545.6B | A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or AmplificationNCT06585488Phase 1a: Number of Participants Experiencing Adverse Events (AEs) | Phase 1 | Terminatedsponsor's stated reason: The Sponsor has made the decision to terminate this study due to the lack of promising efficacy, internal prioritization, and highly competitive landscape. | Drug: BGB-53038, Tislelizumab, Cetuximab | Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Colorectal Cancer, Advanced Pancreatic Ductal Adenocarcinoma, Advanced Gastric Cancer, Advanced Gastroesophageal Junction Cancer, Advanced Esophageal Adenocarcinoma | 47 | 2024-12-13 | 2026-04-23actual | — | 2026-07-08 |
| AZN | AstraZeneca | — | A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid TumoursNCT06147037Evaluate safety and tolerability of [111In]-FPI-2107, FPI-2053, and [225Ac]-FPI-2068 | Phase 1 | Active, not recruiting | Drug: FPI-2053, [111In]-FPI-2107, [225Ac]-FPI-2068 | Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Renal Cell Carcinoma | 13 | 2024-07-31 | 2026-12-31 | in 133 d | 2026-07-07 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of Sigvotatug Vedotin in Advanced Solid TumorsNCT04389632Number of participants with adverse events (AEs) | Phase 1 | Recruiting | Drug: sigvotatug vedotin, pembrolizumab, cisplatin, carboplatin | Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Ovarian Neoplasms, Cutaneous Squamous Cell Cancer, Exocrine Pancreatic Adenocarcinoma, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Stomach Neoplasms | 1,006 | 2020-06-08 | 2027-06-16 | in 300 d | 2026-07-06 |
| CATX | Perspective Therapeutics | $366M | Lead-212 PSV359 Therapy for Patients With Solid TumorsNCT06710756Determination of safety and tolerability of [203Pb]Pb-PSV359 | Phase 1/2 | Recruiting | Drug: [203Pb]Pb-PSV359, [212Pb]Pb-PSV359 | Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Esophageal Cancer, Colorectal Cancer, Ovarian Cancer, Head and Neck Cancer, Sarcoma, Mesothelioma | 112 | 2025-04-28 | 2028-01-31 | in 529 d | 2026-07-06 |
| AZN | AstraZeneca | — | Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2NCT07431281Progression Free Survival (PFS) (Cohort 1 and Cohort 2) | Phase 3 | Recruiting | Drug: Sonesitatug vedotin, Rilvegostomig, Nivolumab, Capecitabine, 5-Fluorouracil, Oxaliplatin, Zolbetuximab, Leucovorin | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer | 2,130 | 2026-02-03 | 2029-08-16 | in 1,092 d | 2026-07-01 |
| 3402.T | Toray Industries, Inc | $12.6B | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid TumorsNCT03872947Frequency of patients experiencing treatment emergent adverse events as assessed by CTCAE v5.0 | Phase 1 | Active, not recruiting | Biological: TRK-950, TRK-950, TRK-950 · Drug: Irinotecan, Leucovorin, 5-FU, Gemcitabine, Cisplatin, Carboplatin, Ramucirumab, Paclitaxel, Nivolumab, Pembrolizumab, Imiquimod Cream, Bevacizumab, PLD | Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer, Ovarian Cancer, Gastric Cancer, Palpable Subcutaneous Malignant Lesions, Renal Cell Carcinoma, Melanoma, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer | 138 | 2019-04-26 | Jun 2026 | — | 2026-06-23 |
| 3402.T | Toray Industries, Inc | $12.6B | A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric CancerNCT06038578Progression free Survival (PFS) | Phase 2 | Recruiting | Biological: TRK-950 · Drug: Ramucirumab, Paclitaxel | Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 146 | 2023-10-04 | 2026-06-30 | — | 2026-06-23 |
| BMY | Bristol-Myers Squibb | $134.9B | Evaluation of Esophagogastric Cancer Treatment With Nivolumab in Daily Clinical PracticeNCT07663786observationalOverall survival (OS) among participants treated with first-line nivolumab | — | Active, not recruiting | Drug: Nivolumab | Esophageal Adenocarcinoma, Gastro-esophageal Junction Adenocarcinoma, Gastric Adenocarcinoma | 726 | 2025-10-09 | 2026-10-01 | in 42 d | 2026-06-23 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study of the Effectiveness and Safety of Nivolumab Plus Chemotherapy in Participants With Untreated Advanced/Recurrent Gastric CancerNCT05334719observationalProgression-free survival (PFS) | — | Completed | — | Stomach Neoplasms | 500 | 2022-06-29 | 2026-01-16actual | — | 2026-06-18 |
| AZN | AstraZeneca | — | A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2NCT07143604Objective Response Rate (ORR) | Phase 2 | Active, not recruiting | Drug: AZD0901 | Gastric Cancer, Gastroesophageal Junction Cancer | 33 | 2025-08-29 | 2026-09-28 | in 39 d | 2026-06-17 |
| GEHC | GE Healthcare | $33.0B | Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)NCT07219238Per-region sensitivity and Per-region specificity of GEH300079 (68Ga) PET/CT imaging to detect PC. | Phase 2/3 | Recruiting | Drug: GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) | Colorectal Cancer, Gastric Cancers, Ovarian Cancers, Pancreatic Ductal Adenocarcinoma | 175 | Oct 2026 | Jun 2029 | ≤ 1,045 d | 2026-06-17 |
| AZN | AstraZeneca | — | A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric CancerNCT06764875Progression free survival (PFS) | Phase 3 | Recruiting | Drug: Rilvegostomig, Trastuzumab deruxtecan, Trastuzumab, Pembrolizumab, 5-fluorouracil, Capecitabine, Cisplatin, Oxaliplatin | HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 840 | 2025-03-01 | 2029-04-27 | in 981 d | 2026-06-16 |
| RXRX | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | $1.7B | Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid TumorsNCT07517198Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Phase 1 | Recruiting | Drug: EXS74539 | Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin, Non-small Cell Lung Cancer (NSCLC), Prostate Cancer, Ovarian Cancer, Renal Carcinoma (Clear and Non-clear Cell), Head and Neck Squamous Cell Carcinoma (HNSCC), Hepatic Cancer, Gastric Cancer, Triple-negative Breast Cancer (TNBC) | 40 | 2026-04-13 | Mar 2029 | ≤ 954 d | 2026-06-10 |
| AMGN | Amgen | $229.9B | Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionNCT05052801Overall Survival | Phase 3 | Completed | Drug: Bemarituzumab, mFOLFOX6, Placebo | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 547 | 2022-03-07 | 2025-06-20actual | — | 2026-05-27 |
| AZN | AstraZeneca | — | Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaNCT05702229ORR (per RECIST 1.1 as assessed by Investigator) | Phase 2 | Recruiting | Drug: Rilvegostomig, Volrustomig, FOLFOX, XELOX, AZD0901, 5-Fluorouracil, Capecitabine | Gastric Cancer | 163 | 2023-01-16 | 2027-11-30 | in 467 d | 2026-05-14 |
| PFE | Pfizer | $155.3B | Safety and Efficacy of Trastuzumab BSNCT04181333results2026-04-14observationalThe Incidence of Adverse Drug Reactions (ADRs) | — | Completed | Drug: TRASTUZUMAB BS | Gastric Cancer | 8 | 2023-08-09 | 2025-03-27actual | — | 2026-04-14 |
| BMY | Bristol-Myers Squibb | $134.9B | Observational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer in FranceNCT06504615observationalOverall survival (OS) | — | Active, not recruiting | Drug: nivolumab + chemotherapy | Gastric Adenocarcinoma, Gastro-esophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma (EAC), Esophageal Squamous Cell Carcinoma (ESCC) | 208 | 2024-12-10 | 2028-08-31 | in 742 d | 2026-04-03 |
| PFE | Pfizer | $155.3B | Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)NCT05382364Percentage of participants with ≥1 adverse event (AE) | Phase 1 | Active, not recruiting | Drug: Tucatinib | Metastatic HER2+ Advanced Breast Cancer, Breast Neoplasms, Gastric or Gastroesophageal Junction Adenocarcinoma (GEC), Colorectal Cancer | 25 | 2022-06-29 | 2026-12-31 | in 133 d | 2026-03-12 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal CancersNCT04430738results2025-09-09Number of Participants With Renal Dose-Limiting Toxicities (DLTs): Phase 1b (Cohort 1A and 1B) | Phase 2 | Active, not recruiting | Drug: tucatinib, trastuzumab, oxaliplatin, leucovorin, fluorouracil, capecitabine, pembrolizumab | Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma, Cholangiocarcinoma, Gallbladder Carcinoma | 40 | 2020-09-15 | 2024-07-31actual | — | 2026-02-24 |
| AZN | AstraZeneca | — | Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid TumorsNCT06005493The number of patients with adverse events | Phase 1/2 | Recruiting | Drug: AZD5863 | Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma | 280 | 2023-07-11 | 2027-07-16 | in 330 d | 2026-02-24 |
| PFE | Pfizer | $155.3B | PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid TumorsNCT05233436Number of participants with Dose-limiting toxicities (DLTs) in Dose Escalation (Part 1) | Phase 1 | Terminatedsponsor's stated reason: Study terminated based on internal business considerations and was not based on safety reasons | Drug: PF-07265028 · Biological: Sasanlimab | Advanced Solid Tumors, Gastric Cancer, Gastroesophageal Junction Cancer, Urothelial Cancer, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinomas | 21 | 2022-02-24 | 2023-10-16actual | — | 2026-02-19 |
| PRLD | Prelude Therapeutics | $459M | A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 MutationNCT06560645Dose Limiting toxicity (DLT) of PRT7732 | Phase 1 | Terminatedsponsor's stated reason: Sponsor decision | Drug: PRT7732 | Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Carcinoma, SMARCA4 Mutation, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Squamous Cell Carcinoma | 42 | 2024-11-04 | 2026-01-28actual | — | 2026-02-02 |
| 4151.T | Kyowa Kirin Co., Ltd. | $8.4B | A Study of KK2269 in Adult Participants With Solid TumorsNCT06266299Number of Subjects Experiencing Dose-limiting Toxicity | Phase 1 | Recruiting | Drug: KK2269, Docetaxel | Advanced Solid Tumor, Metastatic Solid Tumor, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, Non Small Cell Lung Cancer | 101 | 2024-01-18 | Mar 2029 | ≤ 954 d | 2026-01-28 |
| CUE | Cue Biopharma | $2.4B | A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic CancersNCT05360680Dose Limiting Toxicity | Phase 1 | Completed | Drug: CUE-102 | Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Ovarian Cancer | 42 | 2022-06-14 | 2025-03-12actual | — | 2026-01-22 |
| IBRX | ImmunityBio, Inc. | $8.2B | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsNCT03228667ORR, defined as Investigator-assessed CR + PR per RECIST v1.1. | Phase 2 | Active, not recruiting | Drug: N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab, N-803 + Avelumab, N-803 + Durvalumab, N-803 + Pembrolizumab + PD-L1 t-haNK, N-803 + Nivolumab + PD-L1 t-haNK, N-803 + Atezolizumab + PD-L1 t-haNK, N-803 + Avelumab + PD-L1 t-haNK, N-803 + Durvalumab + PD-L1 t-haNK, N-803 + Docetaxel + Pembrolizumab, N-803 + Docetaxel + Nivolumab | Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Renal Cell Carcinoma, Gastric Cancer, Cervical Cancer, Hepatocellular Carcinoma, Microsatellite Instability, Mismatch Repair Deficiency, Colorectal Cancer | 40 | 2018-12-11 | 2029-08-31 | in 1,107 d | 2026-01-14 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of SGN-B6A in Chinese Participants With Advanced Solid TumorsNCT06549816Number of participants with adverse events (AEs) | Phase 1 | Completed | Drug: sigvotatug vedotin | Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 6 | 2024-08-21 | 2025-11-18actual | — | 2025-12-15 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate Nivolumab in Patients With Unresectable Advanced/Metastatic Gastric Cancer and Gastroesophageal Junction CancerNCT06452329observationalTime to progression (TTP) | — | Completed | Drug: Nivolumab | Gastric Cancer, Gastroesophageal Junction Cancer | 260 | 2024-02-28 | 2025-07-29actual | — | 2025-12-04 |
| ELVN | Enliven Therapeutics | $4.4B | ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast CancerNCT06328738Incidence of dose limiting toxicities (DLTs; Phase 1a only) | Phase 1 | Active, not recruiting | Drug: ELVN-002, Trastuzumab, 5-Fluorouracil, Oxaliplatin, Capecitabine, Eribulin, paclitaxel, Leucovorin | HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors, HER2 Amplification, Colorectal Cancer | 275 | 2024-05-30 | Jan 2027 | ≤ 164 d | 2025-11-19 |
| AZN | AstraZeneca | — | A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid CancerNCT04931654Number of participants with adverse events (AE), serious adverse events (SAE) and immune-mediated AEs (imAE) | Phase 1/2 | Active, not recruiting | Drug: AZD7789 | Carcinoma, Non-Small-Cell Lung, Gastric Cancer, Gastroesophageal Junction Cancer | 136 | 2021-09-28 | 2024-12-04actual | — | 2025-10-09 |
| SNY | Sanofi | — | A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)NCT05104567results2025-07-01Cohort A: Objective Response Rate (ORR) | Phase 2 | Completed | Drug: THOR-707, Pembrolizumab, Cetuximab | Oesophageal Squamous Cell Carcinoma, Gastric Cancer, Hepatocellular Carcinoma, Colorectal Cancer, Oesophageal Adenocarcinoma | 138 | 2021-12-09 | 2023-07-26actual | — | 2025-09-24 |
| SNY | Sanofi | — | Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid TumorsNCT05013554Part 1: Dose Escalation Determine the MTD/maximum administered dose (MAD) and RD(s) of SAR443216 | Phase 1 | Terminated | Drug: SAR443216 IV, SAR443216 SC | Neoplasm Malignant, Breast Cancer, Lung Neoplasm Malignant, Gastric Cancer, Neoplasm | 44 | 2021-08-16 | 2024-01-15actual | — | 2025-09-15 |
| TPST | Tempest Therapeutics | $16M | Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid TumorsNCT04344795Determination of maximum tolerated dose and/or recommended Phase 2 dose (RP2D) and optimum dose schedule for TPST-1495 as a single agent and in combination with pembrolizumab | Phase 1 | Completed | Drug: TPST-1495 twice daily, TPST-1495 once daily or on intermittent schedule, Pembrolizumab | Solid Tumor, Colorectal Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Endometrial Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma, Solid Tumors With PIK3Ca Mutation | 89 | 2020-05-06 | 2024-09-25actual | — | 2025-09-12 |
| NRIX | Nurix Therapeutics, Inc. | $2.8B | A Study of NX-1607 in Adults With Advanced MalignanciesNCT05107674Incidence of treatment-emergent adverse events (TEAEs), including Grade ≥ 3 TEAEs, treatment-emergent serious adverse events (SAEs), TEAEs leading to study drug discontinuation, and deaths due to TEAEs | Phase 1 | Recruiting | Drug: NX-1607, Paclitaxel | Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic or Unresectable Melanoma, Non-small Cell Lung Cancer (NSCLC), Metastatic Castration-resistant Prostate Cancer (mCRPC), Malignant Pleural Mesothelioma (MPM), Triple Negative Breast Cancer (TNBC), Metastatic Urothelial Carcinoma, Cervical Cancer, Diffuse Large B Cell Lymphoma (DLBCL), Richter Transformation, Microsatellite Stable Colorectal Carcinoma | 345 | 2021-09-29 | 2026-08-31 | in 11 d | 2025-09-09 |
| RCUS | Arcus Biosciences, Inc. | $3.8B | A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced MalignanciesNCT04772989Percentage of participants with Adverse Events | Phase 1 | Completed | Drug: AB308, Zimberelimab | Advanced Solid Tumor, Non Small Cell Lung Cancer (NSCLC), Melanoma, Cervical Cancer, Multiple Myeloma, Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma (DLBCL), Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer | 94 | 2021-03-19 | 2025-08-25actual | — | 2025-08-28 |
| GH | Guardant Health, Inc. | $21.5B | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy EvaluationNCT05059444observationalDistant Recurrence Free Interval (D-RFi) | — | Recruiting | Diagnostic test: Guardant Reveal | Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer, Invasive Breast Carcinoma, Cutaneous Melanoma, Esophageal Carcinoma, Gastroesophageal Junction Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Squamous Cell Carcinoma of the Head and Neck, Epithelial Ovarian Carcinoma, Fallopian Tube Carcinoma, Endometrial Carcinoma, Renal Cell Carcinoma, Rectal Adenocarcinoma | 2,020 | 2021-09-07 | Aug 2029 | ≤ 1,107 d | 2025-08-22 |
| 4568.T | Daiichi Sankyo | $31.7B | A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in ChinaNCT06585501observationalPercentage of patients receiving first-line, second-line, and third-line anti-tumor regimens | — | Completed | Other: No drug | Gastric Cancer, Gastroesophageal Junction Cancer | 805 | 2024-08-15 | 2025-07-30actual | — | 2025-08-21 |
| EXEL | Exelixis | $13.2B | Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsNCT03170960Dose Escalation: MTD/Recommended Dose | Phase 1 | Active, not recruiting | Drug: cabozantinib, atezolizumab, cabozantinib, cabozantinib | Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Hepatocellular Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Colorectal Cancer, Head and Neck Cancer, Differentiated Thyroid Cancer, Lower Esophageal Cancer | 914 | 2017-09-05 | 2023-02-21actual | — | 2025-08-17 |
| BMY | Bristol-Myers Squibb | $134.9B | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction CancerNCT02872116results2022-06-28Overall Survival (OS) in Participants Treated With Nivolumab Plus Chemotherapy vs Chemotherapy With PD-L1 CPS ≥ 5 | Phase 3 | Completed | Drug: Nivolumab, Ipilimumab, Oxaliplatin, Capecitabine, Leucovorin, Fluorouracil | Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma | 2,031 | 2016-10-12 | 2020-05-27actual | — | 2025-08-07 |
| ALXO | ALX Oncology Inc. | $288M | A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)NCT05002127Phase 2 | Phase 2/3 | Active, not recruiting | Drug: Evorpacept (ALX148), Trastuzumab, Ramucirumab, Paclitaxel | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma | 127 | 2022-01-15 | 2024-05-24actual | — | 2025-08-07 |
| INCY | Incyte Corporation | $24.7B | Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid TumorsNCT02903914results2021-09-30Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | Phase 1 | Completed | Drug: INCB001158, Pembrolizumab | Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC), Gastric Cancer, Head and Neck Cancer, Lung Cancer, Renal Cell Carcinoma (RCC), Bladder Cancer, UC (Urothelial Cancer), Mesothelioma | 260 | 2016-09-14 | 2020-04-30actual | — | 2025-08-05 |
| ARTV | Artiva Biotherapeutics, Inc. | $571M | A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid TumorsNCT05678205Safety: incidence and severity of adverse events and serious adverse events | Phase 1/2 | Withdrawnsponsor's stated reason: Corporate business decision | Drug: AB-201, Cyclophosphamide, Fludarabine | Breast Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 0 | 2023-08-01 | Apr 2027 | ≤ 253 d | 2025-07-30 |
| MDNAF | Medicenna Therapeutics, Inc. | $22M | A Beta-only IL-2 ImmunoTherapY StudyNCT05086692MDNA11 Recommended Dose for Expansion for monotherapy (mRDE) and Recommended Dose for Expansion for combination (cRDE) | Phase 1/2 | Recruiting | Drug: MDNA11, Pembrolizumab (KEYTRUDA®) | Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer Squamous, Non-Small Cell Lung Cancer Non-squamous, Colorectal Cancer (MSI-H), Gastric Cancer, Cervical Cancer, Basal Cell Carcinoma, Bladder Cancer, Merkel Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Cutaneous Squamous Cell Carcinoma, Pleural Mesothelioma, Esophageal Cancer, Endometrial Carcinoma, Solid Tumor, Solid Tumor, Adult, MSI-H Solid Malignant Tumor, Cancer With A High Tumor Mutational Burden, Epithelial Ovarian Carcinoma, Primary Peritoneal Cancer, Gastroesophageal Junction (GEJ) Cancer, Acral Melanoma, Mucosal Melanoma, Cutaneous Melanoma, DMMR Solid Malignant Tumor, Fallopian Tube Cancer, Ovarian Cancer, MSI-H Cancer, DMMR Cancer, Pancreas Adenocarcinoma (MSI-H), Skin Cancer, Viral Cancer, Cervical Cancers, Endometrial Cancer | 115 | 2021-08-27 | 2026-06-30 | — | 2025-07-09 |
| CLDX | Celldex Therapeutics | $3.3B | A Study of CDX-585 in Patients With Advanced MalignanciesNCT05788484Dose escalation: To determine the maximum tolerated dose of CDX-585 and to select the CDX-585 dose(s) for evaluation in tumor-specific expansion cohorts | Phase 1 | Completed | Drug: CDX-585 | Non-small Cell Lung Cancer, Gastric Cancer, Head and Neck Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Bladder Urothelial Carcinoma, Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Renal Cell Carcinoma, Cholangiocarcinoma, Pancreatic Cancer, Other Solid Tumors | 20 | 2023-05-11 | 2025-05-21actual | — | 2025-06-15 |
| MGNX | MacroGenics | $261M | Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ CancerNCT04082364results2025-04-22Number of Participants With Adverse Events of Margetuximab Plus Retifanlimab in Cohort A, as Assessed by CTCAE v5.0 | Phase 2/3 | Completed | Biological: margetuximab, Retifanlimab, Tebotelimab, Trastuzumab · Other: Chemotherapy | Gastric Cancer, Gastroesophageal Junction Cancer, HER2-positive Gastric Cancer | 82 | 2019-09-30 | 2024-01-15actual | — | 2025-06-08 |
| PFE | Pfizer | $155.3B | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.NCT04152018Number of participants with Dose-limiting toxicities (DLT) for Dose Escalation and Dose Finding | Phase 1 | Terminatedsponsor's stated reason: Study termination was based on strategic considerations and not due to specific safety reasons or a request from a regulatory authority. | Drug: PF-06940434, PF-06801591 | Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Lung Squamous Cell Carcinoma, Pancreatic Cancer, Bile Duct Cancer, Endometrial Cancer, Melanoma Cancer, Urothelial Cancer | 85 | 2019-11-13 | 2024-12-10actual | — | 2025-05-28 |
| MNPR | Monopar Therapeutics | $799M | Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid TumorsNCT06337084To assess dosimetry and biodistribution of MNPR-101-DFO*-89Zr | Phase 1 | Recruiting | Drug: MNPR-101-DFO*-89Zr · Diagnostic test: PET/CT Diagnostic Imaging | Solid Tumor, Adult, Bladder Cancer, Urothelial Carcinoma, Triple-negative Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Ovarian Cancer, Pancreatic Cancer | 12 | 2024-05-30 | Apr 2026 | — | 2025-05-22 |
| MNPR | Monopar Therapeutics | $799M | Dose-Escalation of MNPR-101-PCTA-177Lu in Solid TumorsNCT06617169Identify the dose-limiting toxicities (DLTs) of fractionated MNPR-101-PCTA-177Lu dosing and their frequency | Phase 1 | Recruiting | Drug: MNPR-101-PCTA-177Lu | Solid Tumor, Adult, Bladder Cancer, Urothelial Carcinoma, Triple-negative Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Ovarian Cancer, Pancreatic Cancer | 12 | 2024-10-08 | Dec 2026 | ≤ 133 d | 2025-05-21 |
| APRE | Aprea Therapeutics | $8M | Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor MalignanciesNCT04383938results2025-05-13To Evaluate the Safety of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumors. | Phase 1/2 | Completed | Drug: APR-246 (eprenetapopt) + Pembrolizumab | Bladder Cancer, Gastric Cancer, Non Small Cell Lung Cancer, NSCLC, Urothelial Carcinoma, Advanced Solid Tumor | 40 | 2020-06-25 | 2022-04-30actual | — | 2025-05-13 |
| STTK | Shattuck Labs, Inc. | $748M | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or LymphomasNCT03894618results2025-03-14Safety Profile of SL-279252 | Phase 1 | Completed | Drug: SL-279252 | Squamous Cell Carcinoma of the Head and Neck, Melanoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Squamous Cell Carcinoma of the Anus, Squamous Cell Carcinoma of the Cervix, Squamous Cell Carcinoma of the Skin, Renal Cell Carcinoma, Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Mismatch Repair Deficient or MSI-High Solid Tumors | 49 | 2019-03-26 | 2023-05-04actual | — | 2025-04-02 |
| TVRD | Tvardi Therapeutics, Incorporated | $25M | Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced CancersNCT03195699Maximum Tolerated Dose of TTI-101 | Phase 1 | Completed | Drug: TTI-101, TTI-101 | Breast Cancer, Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer, Hepatocellular Cancer, Colorectal Cancer, Gastric Adenocarcinoma, Melanoma, Advanced Cancer | 64 | 2017-11-15 | 2024-06-24actual | — | 2025-03-21 |
| MGNX | MacroGenics | $261M | Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction CancerNCT02689284results2022-08-04Number of Patients With Dose Limiting Toxicities | Phase 1/2 | Completed | Biological: Margetuximab 10 mg/kg, Margetuximab 15 mg, Pembrolizumab | Gastric Cancer, Stomach Cancer, Esophageal Cancer | 95 | Jan 2016 | Jan 2021actual | — | 2025-03-17 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study of Nivolumab Plus Chemotherapy in First Line Treatment of Adult Participants With Advanced or Metastatic Gastric CancerNCT05165264observationalOverall Survival (OS) | — | Active, not recruiting | — | Gastric Cancer | 600 | 2022-02-16 | 2026-12-31 | in 133 d | 2025-03-03 |
| MGNX | MacroGenics | $261M | Safety Study of MGAH22 in HER2-positive CarcinomasNCT01148849Occurrence of Adverse Events and Serious Adverse Events | Phase 1 | Completed | Biological: margetuximab | Breast Cancer, Gastric Cancer | 66 | Jul 2010 | 2022-06-14actual | — | 2025-02-26 |
| BMY | Bristol-Myers Squibb | $134.9B | An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) CancersNCT03662659results2022-05-09BICR-Assessed Objective Response Rate (ORR) in Randomized LAG-3 Positive (>=1 %) Participants | Phase 2 | Completed | Biological: BMS-986213, Nivolumab · Drug: XELOX, FOLFOX, SOX | Gastric Cancer, Cancer of the Stomach, Esophagogastric Junction | 274 | 2018-10-16 | 2020-08-27actual | — | 2025-02-05 |
| LLY | Eli Lilly and Company | $1.15T | International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric CancerNCT02065765expanded access | — | Approved for marketing | Biological: Ramucirumab | Metastatic Gastric Cancer, Metastatic Adenocarcinoma of the Gastroesophageal Junction | — | — | — | — | 2025-01-09 |
| LLY | Eli Lilly and Company | $1.15T | Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in FranceNCT02307812expanded access | — | Approved for marketing | Drug: Ramucirumab, Paclitaxel | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | — | — | — | — | 2025-01-09 |
| 4503.T | Astellas Pharma Inc | $26.0B | A Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) AdenocarcinomaNCT03528629Dose Limiting Toxicities (DLT) in Safety Part | Not applicable | Completed | Drug: Zolbetuximab | Gastric Cancer, Gastro-esophageal Junction (GEJ) Cancer | 18 | 2018-06-08 | 2020-06-09actual | — | 2024-12-02 |
| NVCR | NovoCure Ltd. | $2.0B | Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric AdenocarcinomaNCT04281576Objective response rate | Not applicable | Completed | Device: NovoTTF-100L(P) · Drug: Oxaliplatin, Capecitabine, Trastuzumab | Gastric Cancer, GastroEsophageal Cancer | 28 | 2019-12-19 | 2024-06-07actual | — | 2024-11-14 |
| INBX | Inhibrx Biosciences, Inc | $1.4B | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck CancerNCT03809624Frequency of adverse events of INBRX-105 | Phase 1 | Terminatedsponsor's stated reason: Program terminated due to lack of meaningful efficacy signal. | Drug: INBRX-105 - PDL1x41BB antibody, Pembrolizumab | Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Gastric Adenocarcinoma, Renal Cell Carcinoma, Esophageal Adenocarcinoma, Nasopharyngeal Carcinoma, Oropharyngeal Carcinoma | 160 | 2019-01-30 | 2024-10-03actual | — | 2024-10-23 |
| BNTX | BioNTech SE | — | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract TumorsNCT04683939results2024-10-02Occurrence of Treatment-emergent Adverse Events (TEAEs) Within a Patient Including Grade ≥ 3, Serious, Fatal TEAE by Relationship | Phase 1/2 | Terminatedsponsor's stated reason: Sponsor decision | Drug: BNT141, Nab-paclitaxel, Gemcitabine | Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, Pancreatic Cancer, Biliary Tract Cancer, Cholangiocarcinoma, Metastatic Cancer | 13 | 2022-01-18 | 2023-07-24actual | — | 2024-10-02 |
| LIANY | LianBio LLC | $5M | Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ AdenocarcinomaNCT06206278Objective response rate (ORR) | Phase 2 | Terminatedsponsor's stated reason: Business Reason | Drug: Infigratinib | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 6 | 2023-10-19 | 2024-05-31actual | — | 2024-08-14 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract CancerNCT02443324results2024-07-31Phase 1a: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) | Phase 1 | Completed | Drug: Ramucirumab, Pembrolizumab | Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction, Non-small Cell Lung Cancer, Carcinoma, Transitional Cell, Biliary Tract Cancer | 175 | 2015-07-29 | 2018-08-31actual | — | 2024-07-31 |
| NXTC | NextCure, Inc. | $30M | A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid TumorsNCT04408599results2024-07-25Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0 | Phase 1/2 | Terminatedsponsor's stated reason: Upon completion of the Phase 1 portion of the NC410 monotherapy trial, NextCure focused efforts on a combination trial of NC410 in solid tumors. | Drug: NC410 | Advanced or Metastatic Solid Tumors, Ovarian Cancer, Gastric Cancer, Colo-rectal Cancer | 46 | 2020-06-10 | 2023-07-06actual | — | 2024-07-25 |
| XNCR | Xencor, Inc. | $1.9B | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)NCT03752398Treatment-related adverse events as assessed by CTCAE v4.03 | Phase 1 | Completed | Biological: XmAb®23104, Yervoy® (ipilimumab) | Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma, Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced Solid Tumors, Undifferentiated Pleomorphic Sarcoma | 198 | 2019-05-01 | 2024-02-15actual | — | 2024-07-05 |
| ADCT | ADC Therapeutics S.A. | $131M | Study of ADCT-301 in Patients With Selected Advanced Solid TumorsNCT03621982results2024-06-13Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) | Phase 1 | Terminatedsponsor's stated reason: Cami in combination with pembrolizumab in solid tumors showed signals of immunomodulatory activity. However, the signals were insufficiently compelling at the tested dose/schedule to justify continuation of the study. | Drug: ADCT-301 · Biological: Pembrolizumab | Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Gastric Cancer, Esophageal Cancer, Pancreas Cancer, Bladder Cancer, Renal Cell Carcinoma, Melanoma, Triple-negative Breast Cancer, Ovarian Cancer, Colo-rectal Cancer, Fallopian Tube Cancer | 78 | 2018-11-09 | 2022-12-14actual | — | 2024-06-13 |
| CLDX | Celldex Therapeutics | $3.3B | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced MalignanciesNCT03329950Safety and Tolerability of CDX-1140 as assessed by CTCAE v5.0 | Phase 1 | Completed | Drug: CDX-1140, CDX-301, pembrolizumab, Chemotherapy | Melanoma, Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Renal Cell Carcinoma, Ovarian Cancer, Cholangiocarcinoma, Bladder Urothelial Carcinoma, Pancreatic Adenocarcinoma, Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Head and Neck Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Other Solid Tumors, Diffuse Large B-cell Lymphoma (DLBCL), Mantle Cell Lymphoma, Indolent B-cell Lymphomas, Non-Hodgkin Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Waldenstrom's Disease, Marginal Zone Lymphoma, Mucosa Associated Lymphoid Tissue, Small Lymphocytic Leukemia | 132 | 2017-12-01 | 2022-09-13actual | — | 2024-03-28 |
| AZN | AstraZeneca | — | Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.NCT01924533results2018-11-07Overall Survival | Phase 3 | Completed | Drug: Olaparib, Paclitaxel, Placebo | Gastric Cancer | 525 | 2013-09-03 | 2016-04-04actual | — | 2024-03-22 |
| 4568.T | Daiichi Sankyo Co., Ltd. | $31.7B | Real-World Observational Study to Describe Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer in East AsiaNCT05606094observationalPercentage of Participants Receiving Each Regimen in Each Line of Treatment (LOT) | — | Completed | — | Gastric Cancer | 450 | 2023-03-09 | 2023-11-30actual | — | 2023-12-15 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Gastric Cancer is matched — 11 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Gastric Cancer
- Gastric Adenocarcinoma
- Stomach Neoplasms
- Stomach Cancer
- Advanced Gastric Cancer
- HER2-positive Gastric Cancer
- Gastric or Gastroesophageal Junction Adenocarcinoma
- Metastatic Gastric Adenocarcinoma
- Metastatic Gastric Cancer
- Gastric Cancers
- Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Gastric Cancer” (a text search, wider than this page)